U.S. Markets closed

Omeros Corporation (OMER)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.66-0.39 (-3.53%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.05
Open11.02
Bid10.06 x 800
Ask10.62 x 1300
Day's Range10.57 - 11.02
52 Week Range8.50 - 25.46
Volume541,362
Avg. Volume1,613,481
Market Cap654.72M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.60
  • Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA
    Business Wire

    Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA

    Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved therapy. Narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway and activator of the coagulation cascade, is being studied for the treatment of HSCT-TMA patients at high risk for poor outcomes. Narsoplimab has been awarded Breakthrough Therapy designation by U.S. FDA and is the subject of a rolling Biologics License Application (BLA) for HSCT-TMA. The nonclinical and CMC modules of the rolling BLA have already been submitted, and the final sections of the clinical module are in the publishing phase during which finalized documents are electronically processed and integrated for submission in the format required by FDA.

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For October 20, 2020

    Upgrades * According to BMO Capital, the prior rating for Dave & Buster's Entertainment Inc (NASDAQ: PLAY) was changed from Market Perform to Outperform. In the second quarter, Dave & Buster's Enter showed an EPS of $1.24, compared to $0.90 from the year-ago quarter. At the moment, the stock has a 52-week-high of 48.8 and a 52-week-low of 4.605. Dave & Buster's Enter closed at $17.36 at the end of the last trading period. * According to Goldman Sachs, the prior rating for OGE Energy Corp (NYSE: OGE) was changed from Sell to Neutral. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The current stock performance of OGE Energy shows a 52-week-high of 46.43 and a 52-week-low of 23.005. Moreover, at the end of the last trading period, the closing price was at $31.55. * According to Vertical Research, the prior rating for Lennox International Inc (NYSE: LII) was changed from Sell to Hold. Lennox International earned $3.53 in the third quarter, compared to $3.34 in the year-ago quarter. The stock has a 52-week-high of 297.0 and a 52-week-low of 163.395. At the end of the last trading period, Lennox International closed at $278.49. * For Fortinet Inc (NASDAQ: FTNT), Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of 151.95 and a 52-week-low of 70.2. Moreover, at the end of the last trading period, the closing price was at $128.82. * Jefferies upgraded the previous rating for National Beverage Corp (NASDAQ: FIZZ) from Underperform to Hold. For the first quarter, National Beverage had an EPS of $1.09, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of 86.265 and a 52-week-low of 35.71. At the end of the last trading period, National Beverage closed at $84.48. * RBC Capital upgraded the previous rating for Rayonier Advanced Materials Inc (NYSE: RYAM) from Sector Perform to Outperform. For the second quarter, Rayonier Advanced had an EPS of $0.20, compared to year-ago quarter EPS of $0.35. At the moment, the stock has a 52-week-high of 4.87 and a 52-week-low of 0.9001. Rayonier Advanced closed at $4.09 at the end of the last trading period. * JP Morgan upgraded the previous rating for Brunswick Corp (NYSE: BC) from Neutral to Overweight. In the second quarter, Brunswick showed an EPS of $0.99, compared to $1.45 from the year-ago quarter. The current stock performance of Brunswick shows a 52-week-high of 73.99 and a 52-week-low of 25.22. Moreover, at the end of the last trading period, the closing price was at $62.65. * According to Piper Sandler, the prior rating for Workday Inc (NASDAQ: WDAY) was changed from Neutral to Overweight. Workday earned $0.84 in the second quarter, compared to $0.44 in the year-ago quarter. At the moment, the stock has a 52-week-high of 248.75 and a 52-week-low of 107.75. Workday closed at $227.64 at the end of the last trading period. Downgrades * MKM Partners downgraded the previous rating for Concho Resources Inc (NYSE: CXO) from Buy to Neutral. Concho Resources earned $1.13 in the second quarter, compared to $0.69 in the year-ago quarter. At the moment, the stock has a 52-week-high of 93.34 and a 52-week-low of 33.13. Concho Resources closed at $47.27 at the end of the last trading period. * HC Wainwright & Co. downgraded the previous rating for BioSpecifics Technologies Corp (NASDAQ: BSTC) from Buy to Neutral. BioSpecifics Technologies earned $0.11 in the second quarter, compared to $0.87 in the year-ago quarter. At the moment, the stock has a 52-week-high of 88.69 and a 52-week-low of 42.0. BioSpecifics Technologies closed at $88.69 at the end of the last trading period. * Credit Suisse downgraded the previous rating for Front Yard Residential Corp (NYSE: RESI) from Outperform to Neutral. For the second quarter, Front Yard Residential had an EPS of $0.07, compared to year-ago quarter EPS of $0.47. The stock has a 52-week-high of 13.6899 and a 52-week-low of 6.01. At the end of the last trading period, Front Yard Residential closed at $13.36. * According to Goldman Sachs, the prior rating for Consolidated Edison Inc (NYSE: ED) was changed from Neutral to Sell. In the second quarter, Consolidated Edison showed an EPS of $0.60, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of 95.1 and a 52-week-low of 62.03. At the end of the last trading period, Consolidated Edison closed at $80.79. * According to National Bank Financial, the prior rating for Boyd Gaming Corp (NYSE: BYD) was changed from Outperform to Sector Perform. Boyd Gaming earned $0.98 in the second quarter, compared to $0.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of 36.22 and a 52-week-low of 6.44. Boyd Gaming closed at $34.32 at the end of the last trading period. * For WPX Energy Inc (NYSE: WPX), KeyBanc downgraded the previous rating of Overweight to the current rating Sector Weight. For the second quarter, WPX Energy had an EPS of $0.12, compared to year-ago quarter EPS of $0.09. At the moment, the stock has a 52-week-high of 14.425 and a 52-week-low of 1.94. WPX Energy closed at $4.52 at the end of the last trading period. Initiations * SVB Leerink initiated coverage on Twist Bioscience Corp (NASDAQ: TWST) with a Market Perform rating. The price target for Twist Bioscience is set to $90.00. For the third quarter, Twist Bioscience had an EPS of $0.67, compared to year-ago quarter EPS of $0.92. The current stock performance of Twist Bioscience shows a 52-week-high of 100.3 and a 52-week-low of 18.52. Moreover, at the end of the last trading period, the closing price was at $93.00. * For Venus Concept Inc (NASDAQ: VERO), Ladenburg Thalmann initiated coverage, by setting the current rating at Buy. Interestingly, in the second quarter, Venus Concept's EPS was $0.39. The current stock performance of Venus Concept shows a 52-week-high of 9.0 and a 52-week-low of 2.02. Moreover, at the end of the last trading period, the closing price was at $2.59. * With a current rating of Buy, B of A Securities initiated coverage on Prelude Therapeutics Inc (NASDAQ: PRLD). The price target seems to have been set at $40.00 for Prelude Therapeutics. The current stock performance of Prelude Therapeutics shows a 52-week-high of 50.19 and a 52-week-low of 23.6931. Moreover, at the end of the last trading period, the closing price was at $32.69. * With a current rating of Buy, B of A Securities initiated coverage on PMV Pharmaceuticals Inc (NASDAQ: PMVP). The price target seems to have been set at $42.00 for PMV Pharmaceuticals. At the moment, the stock has a 52-week-high of 42.9316 and a 52-week-low of 31.5. PMV Pharmaceuticals closed at $37.46 at the end of the last trading period. * B of A Securities initiated coverage on Omeros Corp (NASDAQ: OMER) with a Buy rating. The price target for Omeros is set to $21.00. Omeros earned $0.61 in the second quarter, compared to $0.29 in the year-ago quarter. At the moment, the stock has a 52-week-high of 25.46 and a 52-week-low of 8.5. Omeros closed at $11.08 at the end of the last trading period. * With a current rating of Outperform, Cowen & Co. initiated coverage on Chart Industries Inc (NASDAQ: GTLS). The price target seems to have been set at $92.00 for Chart Industries. In the second quarter, Chart Industries showed an EPS of $0.63, compared to $0.68 from the year-ago quarter. The current stock performance of Chart Industries shows a 52-week-high of 85.895 and a 52-week-low of 15.0. Moreover, at the end of the last trading period, the closing price was at $83.10. * With a current rating of Outperform, SVB Leerink initiated coverage on Graybug Vision Inc (NASDAQ: GRAY). The price target seems to have been set at $35.00 for Graybug Vision. The stock has a 52-week-high of 20.74 and a 52-week-low of 12.5. At the end of the last trading period, Graybug Vision closed at $15.90. * Wolfe Research initiated coverage on Verizon Communications Inc (NYSE: VZ) with a Peer Perform rating. The price target for Verizon Communications is set to $62.00. Verizon Communications earned $1.18 in the second quarter, compared to $1.23 in the year-ago quarter. The current stock performance of Verizon Communications shows a 52-week-high of 62.22 and a 52-week-low of 48.84. Moreover, at the end of the last trading period, the closing price was at $57.31. * Wolfe Research initiated coverage on AT&T Inc (NYSE: T) with a Peer Perform rating. The price target for AT&T is set to $31.00. AT&T earned $0.83 in the second quarter, compared to $0.89 in the year-ago quarter. The current stock performance of AT&T shows a 52-week-high of 39.7 and a 52-week-low of 26.08. Moreover, at the end of the last trading period, the closing price was at $26.89. * With a current rating of Outperform, Oppenheimer initiated coverage on Pinduoduo Inc (NASDAQ: PDD). The price target seems to have been set at $100.00 for Pinduoduo. In the second quarter, Pinduoduo showed an EPS of $0.01, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of 98.96 and a 52-week-low of 30.2. Pinduoduo closed at $84.15 at the end of the last trading period. * With a current rating of Buy, Stifel initiated coverage on NuVasive Inc (NASDAQ: NUVA). The price target seems to have been set at $64.00 for NuVasive. NuVasive earned $0.40 in the second quarter, compared to $0.63 in the year-ago quarter. The stock has a 52-week-high of 81.91 and a 52-week-low of 28.55. At the end of the last trading period, NuVasive closed at $52.40. * Piper Sandler initiated coverage on Graybug Vision Inc (NASDAQ: GRAY) with an Overweight rating. The price target for Graybug Vision is set to $27.00. The stock has a 52-week-high of 20.74 and a 52-week-low of 12.5. At the end of the last trading period, Graybug Vision closed at $15.90. * Stifel initiated coverage on Globus Medical Inc (NYSE: GMED) with a Hold rating. The price target for Globus Medical is set to $56.00. Globus Medical earned $0.07 in the second quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of 60.15 and a 52-week-low of 33.41. At the end of the last trading period, Globus Medical closed at $54.79. * Mizuho initiated coverage on bluebird bio Inc (NASDAQ: BLUE) with a Buy rating. The price target for bluebird bio is set to $123.00. In the second quarter, bluebird bio showed an EPS of $0.36, compared to $3.55 from the year-ago quarter. The stock has a 52-week-high of 99.36 and a 52-week-low of 38.95. At the end of the last trading period, bluebird bio closed at $54.55. * Stifel initiated coverage on Alphatec Holdings Inc (NASDAQ: ATEC) with a Buy rating. The price target for Alphatec Holdings is set to $13.00. Alphatec Holdings earned $0.25 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of 11.38 and a 52-week-low of 2.19. Alphatec Holdings closed at $9.88 at the end of the last trading period. * With a current rating of Outperform, Baird initiated coverage on Amphenol Corp (NYSE: APH). The price target seems to have been set at $127.00 for Amphenol. Amphenol earned $0.81 in the second quarter, compared to $0.92 in the year-ago quarter. At the moment, the stock has a 52-week-high of 116.1 and a 52-week-low of 63.05. Amphenol closed at $112.99 at the end of the last trading period. * Compass Point initiated coverage on Mr. Cooper Group Inc (NASDAQ: COOP) with a Buy rating. The price target for Mr. Cooper Group is set to $30.00. In the second quarter, Mr. Cooper Group showed an EPS of $0.77, compared to $0.63 from the year-ago quarter. The current stock performance of Mr. Cooper Group shows a 52-week-high of 24.705 and a 52-week-low of 4.31. Moreover, at the end of the last trading period, the closing price was at $23.73. * With a current rating of Buy, Berenberg initiated coverage on VIA optronics AG (NYSE: VIAO). The price target seems to have been set at $22.00 for VIA optronics. At the moment, the stock has a 52-week-high of 12.4399 and a 52-week-low of 7.04. VIA optronics closed at $7.93 at the end of the last trading period.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Return On Capital Employed Overview: Cara Therapeutics * Return On Capital Employed Overview: Travelers Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
    Business Wire

    Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

    Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made by Jason Cummings, Ph.D., Omeros’ Associate Director for Research. Dr. Cummings’ slide presentation can be viewed at https://investor.omeros.com/presentations.